Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 12 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

4 trials in Phase 3/4

Results Transparency

11%

1 of 9 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

4(36.4%)

Phase 4

3(27.3%)

N/A

2(18.2%)

Phase 1

1(9.1%)

Phase 3

1(9.1%)

11Total

Phase 2(4)

Phase 4(3)

N/A(2)

Phase 1(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials

NCT05371912Not ApplicableCompleted

Enhancement of Behavioral and Cognitive Outcomes in Autism Spectrum Disorder Via Neurostimulation

Role: collaborator

NCT04134819Unknown

Missing Microbes in Infants Born by Cesarean Section

Role: collaborator

NCT01400490Not ApplicableUnknown

Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid Study

Role: collaborator

NCT00988585Phase 1Completed

Evaluation of the Safety and Biologic Effects of an Eicosapentaenoic (EPA)-Enriched Oil

Role: collaborator

NCT00317031Phase 4Completed

Individually Adapted Therapy of Alcoholism

Role: collaborator

NCT00203658Phase 4Completed

Assessment of Long-Term Out-of-Hospital Treatment of Patients With Proximal Deep Vein Thrombosis (DVT) Using Low-Molecular-Weight Heparin (LMWH) Versus LMWH Followed by Warfarin

Role: collaborator

NCT00203580Phase 4Completed

Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study)

Role: collaborator

NCT00196612Phase 3Completed

Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART

Role: collaborator

NCT00196599Phase 2Completed

Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults

Role: collaborator

NCT00002419Phase 2Completed

Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment

Role: collaborator

NCT00002234Phase 2Completed

Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients

Role: collaborator

NCT00007449Phase 2Unknown

Safety and Effectiveness of the Drug DPC 083 in Combination With Nucleoside Analogue Reverse Transcriptase Inhibitors in HIV-1-Infected Patients Who Are Failing Treatment With Nonnucleoside Reverse Transcriptase Inhibitors

Role: lead

All 12 trials loaded